Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Fountain Biopharma Inc.
DescriptionGlycoengineered rituximab, an anti-CD20 antibody
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today